Table of Contents 

5 EXECUTIVE SUMMARY
5 Generics market
5 Biosimilars market
7 GENERICS MARKET DYNAMICS
8 Germany generics volume market share
9 Germany generics value market share
10 Germany generics market size
11 Bibliography
13 GENERICS DRIVERS AND RESISTORS
13 Tendering is widely used to purchase generics
18 Changes to reference pricing system hit producers
19 Action taken to increase generic substitution
19 Germany leads in Europe in terms of pay-for-delay deals
20 German elections of 2013 not expected to have an impact on the generics market
20 Bibliography
23 KEY GENERICS PLAYERS
23 Teva extends dominance in German marketplace through its acquisition of ratiopharm
23 Indian producers use acquisitions to strengthen position in German market
23 Bibliography
25 BIOSIMILARS MARKET DYNAMICS
25 Drivers of biosimilar uptake in the German market
30 Biosimilars approved in the EU
37 Bibliography

List of Figures 
8 Figure 1: Germany – comparison of generics volume market share versus other pharmaceutical
markets (%), 2010–12
9 Figure 2: Germany – comparison of generics value market share versus other pharmaceutical
markets (%), 2010–12
10 Figure 3: Germany – comparison of generics market size versus other pharmaceutical markets
(%), 2010–12
13 Figure 4: Germany – key factors influencing the generics industry
15 Figure 5: Germany – nationwide AOK contract recipients, rounds 7–11, 2012–15
25 Figure 6: Germany – key factors influencing the biosimilars industry, 2013
36 Figure 7: Germany – drivers and resistors to biosimilar monoclonal antibody entry, 2013

List of Tables
7 Table 1: Germany – comparison of generics penetration versus other pharmaceutical markets
17 Table 2: Successful bidders in the sixth round of tenders operated by spectrumK
23 Table 3: Germany – key M&A activity involving generics producers, 2006–13
27 Table 4: Germany – biologic and biosimilar prices listed in the German National Drug
Formulary, 2013
30 Table 5: Biosimilars approved, withdrawn, and rejected in the EU, up to October 2013